男性全膀胱切除后下尿路功能重建——附120例报告

目的 改良全膀胱切除和原位新膀胱术治疗浸润性膀胱癌的临床经验.方法 采用改良全膀胱切除和原位新膀胱术治疗局部浸润性膀胱癌患者120例,均为男性,平均年龄55.6岁.120例中移行细胞癌113例,鳞癌3例,腺癌4例.TNM临床分期T2N0M0101例、T3N0M0 7例、T3N1M0 2例.统计手术时间、术中出血和输血量,对新膀胱功能、并发症、肿瘤控制和病人生存情况进行随访分析.结果 120例患者无手术死亡,手术时间185～332分钟,平均254分钟.术中出血150～1270 ml,输血40例.病理分期T1N0M0 3例,T2N0M0 111例,T3aN0M0、T3aN1M0和T3bN1M0各2例.随访4～71个月,平均37个月.111例无瘤生存,因肿瘤死亡9例.新膀胱白天控尿良好112例(93.3%),夜间控尿良好95例(79.2%).残余尿量0～100 ml 112例,101～250 ml 8例.主要并发症:切口裂开3例,二次缝合治愈;输尿管吻合口漏1例,再吻合后治愈;输尿管口狭窄4侧,2侧经内镜下切开和扩张纠正,2侧行输尿管新膀胱再吻合治愈.输尿管口粘连4侧,经内镜下手术纠正;严重肠梗阻3例和慢性酸中毒低钾2例,均经内科处理纠正.结论 改良全膀胱切除和原位新膀胱术后严重并发症少、肿瘤控制满意,重建的新膀胱功能良好,能较好保持患者的生活质量,是目前治疗浸润性膀胱癌最理想的方法之一.     

膀胱全切后改良肠道原位新膀胱下尿路功能性重建(附15例疗效分析)

背景与目的：膀胱全切后患者的生活质量受尿流改道方式影响,可控性或非可控性尿流改道后患者不能自主排尿、生活质量差;而肠道原位新膀胱术后患者可自主排尿,生活质量改善,但有排空不良和控尿不全等问题。本文报告改良肠道原位新膀胱术在膀胱全切后下尿路功能性重建中的经验。方法：对15例局部浸润性膀胱癌患者在根治性膀胱切除后利用改良肠道原位新膀胱术（回肠新膀胱3例,乙状结肠新膀胱12例）做下尿路功能性重建。术后随访3-30个月（其中9例随访超过16个月）,对这些患者术后新膀胱功能、控尿和排尿功能、性功能、上尿路形态和功能、血电解质和生活质量进行评价。结果：全部患者自主排尿,无需导尿。13例患者昼夜完全控尿;1例患者白天控尿良好,夜间有少量漏尿;另1例女性患者有中度张力性尿失禁。膀胱容量240-640ml,残余尿量0-250ml。全部患者总肾功能正常,14例血电解质正常;慢性代谢性酸中毒和输尿管扩张各1例。9例男性患者保留性功能。13例患者恢复工作。全部患者对新膀胱功能满意。结论：改良肠道原位新膀胱术后下尿路的控尿和排尿功能良好,是目前根治性膀胱切除后理想的下尿路重建方法。     

全膀胱切除和原位新膀胱术治疗女性浸润性胱膀癌患者(附8例报告)

背景与目的全膀胱切除和原位新膀胱广泛用于治疗男性浸润性膀胱癌,效果良好,但用于女性浸润性膀胱癌的经验很少。本研究的目的是探讨女性全膀胱切除和乙状结肠原位新膀胱的临床效果。方法回顾性分析2002年1月至2003年10月中山大学肿瘤防治中心应用全膀胱切除和乙状结肠原位新膀胱术治疗的8例女性浸润性膀胱癌的临床资料。结果手术均获成功。随访6～24个月(平均18个月),6例无瘤生存,2例分别于术后6个月和12个月出现盆腔复发。全部患者均能自主排尿。4例昼夜完全控尿,另4例白天完全控尿,夜间有少许漏尿。1例术后3个月发现肾输尿管轻度积水,观察3个月后自然消退。血电解质和肾功能均正常。结论女性膀胱癌患者行全膀胱切除和乙状结肠原位新膀胱术后,肿瘤控制及新膀胱功能良好,但夜间控尿能力较差。     

经尿道辅助单孔腹腔镜下根治性膀胱切除联合原位回肠新膀胱术的疗效及安全性

目的:探讨单孔腹腔镜下根治性膀胱切除术联合原位回肠新膀胱术的疗效及安全性。方法:选取2017年01月至2019年12月于本中心收治的17例膀胱癌患者,其中7例患者在经尿道途径的辅助下行单孔腹腔镜根治性膀胱切除术联合原位回肠新膀胱术;另外10例为对照组,行多孔腹腔镜下根治性膀胱切除术联合原位回肠新膀胱术,并对两组患者围手术期资料、手术并发症以及术后随访情况进行分析。结果:两组共17例膀胱癌患者均顺利完成手术,无中转开放手术。两组患者的年龄、体质量指数（body mass index,BMI)等差异均无统计学意义（P＞0.05）。单孔组与对照组平均手术时间分别为（341.4±52.1）min和（333.0±59.5）min,术中平均出血量分别为（206.4±104.6）mL和（190.5±82.3）mL,盆腔淋巴结清扫平均个数分别为17（7~22）个和18（12~23）个,术后平均住院天数分别为（25.1±5.4）d和（26.8±6.0）d,差异均无统计学意义（P＞0.05）。而单孔组在术后VAS疼痛评分和切口满意度评分上则优于对照组（P＜0.05）。其中单孔组患者术后随访12个月时患者的最大尿流量、最大膀胱容量、最大膀胱充盈量均明显比6个月时高,而随访12个月时患者的残余尿量较6个月时低,差异均具有统计学意义（P＜0.05）。结论:经尿道辅助单孔腹腔镜下根治性膀胱切除术联合原位回肠新膀胱术是安全可行的,且术后的新膀胱功能较为良好。     

Survival after cystectomy for invasive bladder cancer

Aim

To determine the difference in survival after cystectomy between patients presenting with primary muscle infiltrating bladder cancer and patients with progression to muscle infiltration after treatment for initial non-muscle-invasive bladder cancer (NMIBC).

Patients and Methods

We retrospectively analyzed the files of 188 patients who underwent cystectomy for transitional cell carcinoma between 1987 and 2005. Two groups were defined: patients presenting with muscle-invasive tumours and those progressing to muscle invasion after initial treatment. This second group was further divided into low-intermediate and high risk according to the EAU grouping for NMIBC.

Results

The 5-year disease specific survival (95% confidence intervals) for all patients was 50%(42–59%); 49%(40–60%) in the primary muscle infiltrating group and 52%(37–74%) in the progressive group (p = ns). The 5-year disease specific survival in the progressive group according to EAU risk groups was 75%(58–97%) for the initially diagnosed low-intermediate risk tumours and 35%(17–71%) for the initially diagnosed high-risk tumours (p = 0.015). The percentage of patients with non-locally confined tumours (pT3/4-N0//any pT-N+) was 31%//45% and 24%//46% in the primary muscle infiltrating and progressive group, respectively.

Conclusions

Despite close observation of patients treated for non-muscle-invasive bladder cancer, the survival of patients who progress to muscle invasion is not better than survival of patients presenting with primary muscle infiltrating cancer. Patients with high-risk non-invasive tumours (EAU risk-categories) who progress to muscle-invasive disease have a worse prognosis compared to patients with low or intermediate risk tumours.     

原位回肠膀胱对上尿路功能影响的回顾性分析

目的:探讨原位回肠膀胱对上尿路功能的影响。方法:评估2006年3月至2011年6月陕西省核工业二一五医院泌尿外科收治的34例肌层浸润性膀胱尿路上皮癌行膀胱全切W形原位回肠代膀胱患者的上尿路功能,所有病例随访时间5年以上,均无复发及转移。评估项目包括肌酐测定、泌尿系B超测定膀胱残余尿量及肾积水量、膀胱造影明确有无尿液返流。结果:术后2年,膀胱造影5例（14.7%）患者出现反流致轻度肾积水,与术前比较差异无统计学意义（χ2=2.110,P>0.05）,术后5年,膀胱造影6例（17.6%）患者出现反流致轻度肾积水,与术前比较差异无统计学意义（χ2=1.531,P>0.05）;术前血肌酐（77.32±13.78） mmol/L,术后2年血肌酐（78.50±12.37） mmol/L（t=-1.93,P>0.05）;术后5年血肌酐（82.15±22.49） mmol/L（t=-2.36,P>0.05）,无统计学差异,且均在正常范围。术后2年膀胱容量（413±19） ml,残余尿量（57.3±36.1） ml,术后5年膀胱容量（423±17） ml,残余尿量（53.3±33.7） ml,残余尿量差异无统计学意义（t=-0.29,P>0.05）。结论:原位W型回肠膀胱可作为膀胱全切术后理想的代膀胱术式,对上尿路功能影响较轻。     

Urinary diversion and morbidity after radical cystectomy for bladder cancer

BACKGROUND:

The rate of continent urinary diversion after radical cystectomy for bladder cancer varies by patient and provider characteristics. Demonstration of equivalent complication rates, independent of diversion type, may decrease provider reluctance to perform continent reconstructions. The authors sought to determine whether continent reconstructions confer increased complication rates after radical cystectomy.

METHODS:

From the Nationwide Inpatient Sample, the authors used International Classification of Disease (ICD‐9) codes to identify subjects who underwent radical cystectomy for bladder cancer during 2001‐2005. They determined acute postoperative medical and surgical complications from ICD‐9 codes and compared complication rates by reconstruction type using the nearest neighbor propensity score matching method and multivariate logistic regression models.

RESULTS:

Adjusting for case‐mix differences between reconstructive groups, continent diversions conferred a lower risk of medical, surgical, and disposition‐related complications that was statistically significant for bowel (3.1% lower risk; 95% confidence interval [95% CI], ?6.8% to ?0.1%), urinary (1.2% lower risk; 95% CI, ?2.3%, to ?0.4%), and other surgical complications (3.0% lower risk; 95% CI, ?6.2% to ?0.4%), and discharge other than home (8.2% lower risk; 95% CI, ?12.1% to ?4.6%) compared with ileal conduit subjects. Older age and certain comorbid conditions, including congestive heart failure and preoperative weight loss, were associated with significantly increased odds of postoperative medical and surgical complications in all subjects.

CONCLUSIONS:

Mode of urinary diversion after radical cystectomy for bladder cancer is not associated with increased risk of immediate postoperative complications. These results may encourage broader consideration of continent urinary diversion without concern for increased complication rates. Cancer 2010. © 2010 American Cancer Society.     

腹腔镜根治性膀胱切除+原位回肠新膀胱术治疗浸润性膀胱癌的临床疗效分析

目的:探讨腹腔镜根治性膀胱切除+原位回肠新膀胱术治疗浸润性膀胱癌的临床疗效.方法:回顾性分析2010年2月至2015年11月于蚌埠医学院第一附属医院行腹腔镜根治性膀胱切除+原位回肠新膀胱术的32例浸润性膀胱癌患者的临床资料,对手术方法(腹腔镜根治性膀胱切除+原位回肠新膀胱术)、围手术期资料、新膀胱功能、术后并发症以及肿瘤控制情况等进行分析.结果:成功随访32例,随访时间12 ～ 53个月,平均随访27个月,均为男性;所有患者手术均由同一术者顺利完成,手术时间310 ～530 min,平均370 min;术中出血300～ 850 ml,平均485 ml;术后3～5天肠道开始恢复功能;淋巴结清扫数目8～31个,平均16个;手术切缘均无阳性结果;术后12个月与6个月相比较,最大尿流率(15.2±1.3vs11.4±1.2 ml,P＜0.01)、最大膀胱容量(372.8±52.2 vs 247.9±60.3 ml,P＜0.01)、残余尿量(23.8 ±9.6 vs 39.6±11.7 ml,P＜0.01)、最大膀胱充盈压(33.7 ±5.7 vs 25.1±6.8 cmH2O,P＜O.01)、最大膀胱排尿压(63.7±15.9 vs62.9±17.6 cmH2O,P＞0.05)、膀胱顺应性(26.2±12.6 vs 25.7±13.3 cmH2O,P＞0.05)以及昼/夜控尿率(91％/81％ vs 84％/72％).术后近期并发症发生率为18.8％(6/32),远期并发症发生率为25.0％(8/32);随访期间,肿瘤局部复发率和远处转移率分别为6.3％ (2/32)和12.5％(4/32).结论:腹腔镜根治性膀胱切除+原位回肠新膀胱术是安全可行的,具有术后控尿效果好、满意的新膀胱功能和肿瘤控制效果等优点,是治疗浸润性膀胱癌的优先选择.     

原位回盲肠新膀胱术的初步研究

目的:探讨逆行全膀胱切除术后原位回盲肠新膀胱术的手术方式、近期疗效和尿流动力学特点。方法:回顾性分析2018年11月至2019年8月我科收治并行原位回盲肠新膀胱术膀胱癌患者4例,所有患者先行腹膜外逆行根治性全膀胱切除,截取回盲肠构建新膀胱,再将新膀胱与尿道吻合重建尿流通道。术后定期复查尿动力、肾功能、彩超等检查。结果:本组患者随访6~16个月,术后初期患者均有不同程度溢尿现象,3个月后逐步恢复并能良好控尿。1例术后出现尿道吻合口轻度狭窄并输尿管返流。新膀胱最大储尿容量(401.7±53.0)ml,储尿期膀胱内压(19.0±5.7)cmH2O,尿道闭合压(53.6±9.4)cmH2O,储尿期膀胱内压明显小于尿道闭合压,最大尿流率(18.7±1.5)ml/s,平均残余尿量(21.3±4.4)ml。结论:全膀胱切除术后原位回盲肠新膀胱术具有储尿囊容量大、压力低、可控性好、操作简单的优点,是一种较理想的尿流改道方式。     

Recurrent urinary tract infection and risk of bladder cancer in the Nijmegen bladder cancer study

Background:

Controversy exists on whether urinary tract infection (UTI) is a risk factor for urinary bladder cancer (UBC). Here, the association is investigated using data from one of the largest bladder cancer case–control studies worldwide.

Methods:

Information on (i) history and age at onset of regular cystitis (‘regular low-UTI'') and (ii) number and age at onset of UTI treated with antibiotics (‘UTI-ab'') from 1809 UBC patients and 4370 controls was analysed. Odds ratios (ORs) and 95% confidence intervals (CI) adjusted for age, education, smoking, and use of aspirin/ibuprofen were generated, for men and women separately.

Results:

Regular low-UTI was associated with an increased UBC risk (men: OR (95% CI) 6.6 (4.2–11); women: 2.7 (2.0–3.5)), with stronger effects in muscle-invasive UBC. Statistically significant decreased risks (ORs ∼0.65) were observed for up to five UTI-ab, specifically in those who (had) smoked and experienced UTI-ab at a younger age. In women, UTI experienced after menopause was associated with a higher UBC risk, irrespective of the number of episodes.

Conclusions:

Regular cystitis is positively associated with UBC risk. In contrast, a limited number of episodes of UTI treated with antibiotics is associated with decreased UBC risk, but not in never-smokers and postmenopausal women.